预期寿命有限前列腺癌患者中观察等待的过度治疗与利用不足:密歇根泌尿外科质量改进协作组登记分析
基于密歇根泌尿外科质量改进协作组登记,纳入2012至2018年诊断的预期寿命<10年的前列腺癌患者2393例,评估观察等待(WW)与治疗的使用率及管理决定因素。总体WW仅8.1%,主动监测(AS)23.3%,放疗25%,前列腺切除术11.2%,近距离放疗3.6%。在NCCN低危患者(n=358)中WW为15.1%,AS为69.3%,且不同实践间管理差异大,提示WW利用不足和过度治疗。
要点
- 预期寿命<10年前列腺癌患者中观察等待使用率仅8.1%,远低于主动监测的23.3%。
- NCCN低危患者中观察等待占15.1%,主动监测占69.3%,不同实践间WW比例6%-35%差异大。
- 年龄较大与接受主动监测或治疗(相对于观察等待)的可能性降低相关。
核心结论
- 在预期寿命<10年的前列腺癌患者中,观察等待利用不足,低危和有利风险患者存在过度治疗,且实践层面管理差异大。
研究设计与样本
- 回顾性登记分析,纳入密歇根泌尿外科质量改进协作组登记中2012至2018年诊断的前列腺癌且预期寿命<10年的患者2393例。
主要发现
- 总体观察等待8.1%,主动监测23.3%,放疗25%,前列腺切除术11.2%,近距离放疗3.6%。
- NCCN低危患者(n=358)中观察等待15.1%,主动监测69.3%,放疗4.2%,前列腺切除术6.7%,近距离放疗2.5%。
- 低危患者管理在不同实践间差异大:观察等待6%-35%,主动监测44%-81%,确定性治疗0%-30%。
- 年龄较大与接受主动监测(相对于观察等待)的可能性降低相关(OR 0.88,P<.001),也与接受治疗(相对于观察等待)的可能性降低相关(OR 0.83,P<.0001)。
- 存在≥cT2疾病(OR 8.55,P=.014)和更多阳性活检针数(OR 1.41,P=.014)与接受治疗(相对于观察等待)的可能性增加相关;Charlson合并症评分1 vs 0(OR 0.23,P=.043)与接受治疗的可能性降低相关。
临床怎么用
- 对预期寿命<10年的前列腺癌患者,尤其是低危患者,应更充分评估观察等待的适用性,减少不必要的确定性治疗。
- 临床决策需考虑年龄、合并症、临床分期和活检阳性针数等因素,并与患者充分沟通。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine rates of watchful waiting (WW) vs treatment in prostate cancer (PCa) and limited life expectancy (LE) and assess determinants of management. MATERIALS AND METHODS: Patients diagnosed with PCa between 2012 and 2018 with <10 years LE were identified from the Michigan Urologic Surgery Improvement Collaborative registry. Multinomial logistic regression models were used to identify factors associated with management choice among NCCN low-risk PCa patients. Data from high-volume practices were analyzed to understand practice variation. RESULTS: Total 2393 patients were included. Overall, WW was performed in 8.1% compared to 23.3%, 25%, 11.2%, and 3.6% who underwent AS, radiation (XRT), prostatectomy (RP), and brachytherapy (BT), respectively. In men with NCCN low-risk disease (n = 358), WW was performed in 15.1%, compared to AS (69.3%), XRT (4.2%), RP (6.7%), and BT (2.5%). There was wide variation in management among practices in low-risk men; WW (6%-35%), AS (44%-81%), and definitive treatment (0%-30%). Older age was associated with less likelihood of undergoing AS vs WW (odds ratio [OR] 0.88, P < .001) or treatment vs WW (OR 0.83, P < .0001). Presence of ≥cT2 disease (OR 8.55, P = .014) and greater number of positive biopsy cores (OR 1.41, P = .014) was associated with greater likelihood of treatment vs WW and Charlson comorbidity score of 1 vs 0 (OR 0.23, P = .043) was associated with less likelihood of treatment vs WW. CONCLUSION: Wide practice level variation exists in management for patients with low- and favorable-risk PCa and <10-year LE. Utilization of WW is poor, suggesting overtreatment in men who will experience little benefit.
引用
- Singhal U, Tosoian JJ, Qi J, et al. Overtreatment and Underutilization of Watchful Waiting in Men With Limited Life Expectancy: An Analysis of the Michigan Urological Surgery Improvement Collaborative Registry. Urology. 2020. PMID: 32777369. doi:10.1016/j.urology.2020.07.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。